Ocrelizumab-induced psoriasiform dermatitis in a patient with multiple sclerosis
Published Web Locationhttps://doi.org/10.5070/D3247040917
Multiple Sclerosis (MS) is a chronic autoimmune disease that presents with a wide variety of sensory and motor deficiencies. New medications targeting B cells have been approved to treat MS, but the side effect profile has not been widely explored. Herein, we report a case of drug-induced psoriasiform dermatitis following ocrelizumab treatment. Physicians should be cognizant of this possible side effect in patients receiving treatment for MS.